Blue Trust Inc’s Cytosorbents Corp CTSO Stock Holding History

Blue Trust Inc’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-218	Closed	–	–	2275
2022 Q3	$0	Buy	+218	New	+$426	﹤0.01%	2134

Other funds holding CTSO

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blue Trust Inc's CTSO Position: Q4 2022 in Review

Blue Trust Inc sold out of Cytosorbents Corp (CTSO) in Q4 2022, closing a stake of 218 shares.

Blue Trust Inc first reported a position in CTSO in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 53 funds tracked by Wall St. Rank hold CTSO as of Q4 2022.

Blue Trust Inc reported no remaining Cytosorbents Corp position as of Q4 2022 after selling out during the quarter.
Blue Trust Inc sold 218 Cytosorbents Corp shares in Q4 2022.
Blue Trust Inc first reported a position in Cytosorbents Corp in Q3 2022 and held it in 1 quarter.
Blue Trust Inc's Cytosorbents Corp position peaked at $0 in Q3 2022.
53 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2022.

Based on Blue Trust Inc's 13F filing for Q4 2022, filed 17 Jan 2023.